Here are five things to know.
1. The framework breaks down the value of drugs into two main concepts: long-term value for money and short-term affordability.
2. Aspects of long-term value include comparative clinical effectiveness, incremental cost-effectiveness, contextual considerations and other benefits or disadvantages. Short-term affordability focuses on potential budget impact, according to the report.
3. More than 50 organizations submitted more than 300 pages of comments and suggestions for the framework during a national public comment period in late 2016, according to the report.
4. ICER hopes the framework will help inform decisions aimed at achieving sustainable access to high value care for all patients, according to the report.
5. The nonprofit is taking on an influential role in the drug industry — payers already cite ICER’s work when negotiating prices with drug companies, reports STAT.
More articles on supply chain:
Shifting drug production back to US could raise prices: 5 takeaways
5 ways to prepare your supply chain for a disaster
Mayo Clinic physician: A stripped down FDA would be ‘chaotic’
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.